JOCELYN URBANO: Open Payments
NPI 1770037467 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,569 in 13 payments from 11 companies in 2025. Trend: 2023 $1,751 · 2024 $2,195 · 2025 $1,569
Food & beverage: $1,569
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $348 |
| Dexcom, Inc. | 1 | $150 |
| Janssen Pharmaceuticals, Inc | 1 | $146 |
| Corcept Therapeutics | 1 | $127 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Supernus Pharmaceuticals, Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $121 |
| KYOWA KIRIN, INC. | 1 | $110 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $107 |
Products named: DEXCOM G7 GSS (161), INVEGA SUSTENNA, Korlym, REXULTI, Auvelity, Qelbree, GATTEX, CAPLYTA.
Industry payments across TX — which companies pay providers there.
